157 related articles for article (PubMed ID: 28903316)
1. MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas.
Laroche A; Chaire V; Algeo MP; Karanian M; Fourneaux B; Italiano A
Oncotarget; 2017 Aug; 8(33):53968-53977. PubMed ID: 28903316
[TBL] [Abstract][Full Text] [Related]
2. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting.
Dadone-Montaudié B; Laroche-Clary A; Mongis A; Chamorey E; Mauro ID; Chaire V; Finetti P; Schiappa R; Le Loarer F; Birtwisle-Peyrottes I; Michiels JF; Bertucci F; Pedeutour F; Italiano A; Bianchini L
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33092134
[TBL] [Abstract][Full Text] [Related]
4. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
[TBL] [Abstract][Full Text] [Related]
5. Detection of
Rekhi B; Karnik N; Agrawal R; Shetty O; Patkar S
Indian J Pathol Microbiol; 2022; 65(1):65-75. PubMed ID: 35074968
[TBL] [Abstract][Full Text] [Related]
6. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
[TBL] [Abstract][Full Text] [Related]
7. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
[TBL] [Abstract][Full Text] [Related]
8. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
Creytens D; Van Gorp J; Speel EJ; Ferdinande L
Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
[TBL] [Abstract][Full Text] [Related]
10. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
Mod Pathol; 2024 Apr; 37(6):100494. PubMed ID: 38621503
[TBL] [Abstract][Full Text] [Related]
11. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
[TBL] [Abstract][Full Text] [Related]
12. MDM2 Antagonists Induce a Paradoxical Activation of Erk1/2 through a P53-Dependent Mechanism in Dedifferentiated Liposarcomas: Implications for Combinatorial Strategies.
Roy S; Laroche-Clary A; Verbeke S; Derieppe MA; Italiano A
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32806555
[TBL] [Abstract][Full Text] [Related]
13. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
Somaiah N; Tap W
Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
[TBL] [Abstract][Full Text] [Related]
14. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
[TBL] [Abstract][Full Text] [Related]
15. Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.
Cassinelli G; Pasquali S; Lanzi C
Front Oncol; 2022; 12():965261. PubMed ID: 36119484
[TBL] [Abstract][Full Text] [Related]
16. Expression of the preadipocyte marker ZFP423 is dysregulated between well-differentiated and dedifferentiated liposarcoma.
Dang TN; Tiongco RP; Brown LM; Taylor JL; Lyons JM; Lau FH; Floyd ZE
BMC Cancer; 2022 Mar; 22(1):300. PubMed ID: 35313831
[TBL] [Abstract][Full Text] [Related]
17. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
[TBL] [Abstract][Full Text] [Related]
18. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma.
Asano N; Yoshida A; Mitani S; Kobayashi E; Shiotani B; Komiyama M; Fujimoto H; Chuman H; Morioka H; Matsumoto M; Nakamura M; Kubo T; Kato M; Kohno T; Kawai A; Kondo T; Ichikawa H
Oncotarget; 2017 Feb; 8(8):12941-12952. PubMed ID: 28099935
[TBL] [Abstract][Full Text] [Related]
19. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
20. Degree of
Bill KLJ; Seligson ND; Hays JL; Awasthi A; Demoret B; Stets CW; Duggan MC; Bupathi M; Brock GN; Millis SZ; Shakya R; Timmers CD; Wakely PE; Pollock RE; Chen JL
Oncologist; 2019 Jul; 24(7):989-996. PubMed ID: 31019022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]